Last reviewed · How we verify
NCT03785834
The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis
trial testing Punch Biopsy in Cellulitis in 56 participants. Completed in 31 December 2024.
1 June 2024
Quick facts
| Lead sponsor | Ohio State University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 25 May 2018 |
| Primary completion | 1 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Punch Biopsy
Conditions studied
- Cellulitis — all drugs for Cellulitis →
- Pseudocellulitis — all drugs for Pseudocellulitis →
Sponsor
Ohio State University
Who can join
Adults 18 to 99, any sex, with Cellulitis or Pseudocellulitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Investigators wish to study the value of dermatologic testing assessments in differentiating between cellulitis and pseudocellulitis in the inpatient setting. The Investigators propose that by utilizing cutaneous biopsies and tissue cultures in patients that have been admitted to inpatient internal medicine teams, the investigators may be able to improve multiple measures of hospital efficiency in patients presenting with cellulitis-like symptoms, by more accurately recognizing cellulitis from pseudocellulitis. The patient will undergo encrypted digital imaging for his or her condition. This image will then be sent to the study investigators, along with basic clinical information on the skin evaluation form. The study investigators will develop a differential diagnosis and then the patient will undergo a skin biopsy. The patient will then be randomized to one of two arms using a random number generator: A) Skin biopsies and tissue cultures recorded and published in patient's medical chart as they would be in a standard of care procedure B) Skin biopsies and tissue cultures consultation performed but not published in the patient's medical chart unless medically necessary. Information will be collected from medical records in IHIS. Patients will be contacted by phone 30 days after discharge.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Skin biopsies are associated with a lower risk of rehospitalization among hospitalized patients with skin and soft tissue infections: a cross-sectional study.
Libson K, Johnson K, Plaza JA, Chung C, et al · · 2023 · cited 2× · PMID 37139990 · DOI 10.1111/ijd.16705 -
The effect of histopathologic analysis and tissue cultures on inpatient management of cellulitis: a randomized control trial.
Lause M, Hansen E, Libson K, Pettit C, et al · · 2024 · PMID 39042316 · DOI 10.1007/s00403-024-03224-5
Verify or expand the search:
- PubMed search for NCT03785834
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Punch Biopsy
Trials testing the same drug.
- NCT06205615 — Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B · Phase 2 · completed
- NCT07414797 — Discomfort Following Oral Biopsy Comparing Laser and Punch Biopsy · NA · completed
- NCT05393713 — Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study · Phase 1 · terminated
- NCT04652960 — Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome · Phase 1 · active not recruiting
- NCT04541017 — Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) · Phase 1, PHASE2 · terminated
Other recruiting trials for Cellulitis
Currently open trials in the same condition.
- NCT06715306 — Intravenous Versus Oral Treatment of the Main Acute Infections · NA · recruiting
- NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
Other Ohio State University trials
Trials by the same sponsor.
- NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
- NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
- NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03785834 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03785834.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing